NaB reduces the risk of non-alcoholic fatty liver disease (NAFLD) by inhibiting the mRNA levels of fatty acid synthase and increasing the mRNA levels of fatty acid oxidation-associated Cpt1a expression. This evidence concerns the gene CPT1A and metabolic dysfunction-associated steatotic liver disease.